A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Prostate Cancer

Treatments: Drug: BMS-641988 (AR#2)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00644488

CA185-005

Details and patient eligibility

About

The purpose of this clinical study is to assess the safety and tolerability of BMS-641988 once daily orally in Japanese patients with castration resistant prostate cancer

Enrollment: 7 patients

Sex: Male

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients with castration-resistant prostate cancer and serum testosterone ≤50 ng/dL progressive to current therapy who satisfy the inclusion and exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

7 participants in 1 patient group

A1

Experimental group

Description:

Active

Treatment:

Drug: BMS-641988 (AR#2)